Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Everolimus (Primary) ; Bendamustine
- Indications Haematological malignancies
- Focus Adverse reactions
- 27 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 19 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.